logo BDSP

Base documentaire

  1. Assessing the benefits of lipid-lowering therapy.

    Article - En anglais

    In recent years, a substantial body of evidence has emerged to support the use of lipid-lowering therapy in the prevention of coronary artery disease, and many physician groups have endors the management of dyslipidemia in at-risk patients.

    An important consideration in such endorsements has been the issue of the safety of lipid intervention ; many early primary-and secondary-prevention studies reported either no reduction in all-cause mortality rates or an increase in non-coronary artery disease mortality rates in treated patients. ese observations raised serious concerns about the safety of such therapy.

    However, 2 landmark studies, the Scandinavian Simvastatin Survival Study (4S) and the West of Scotland Coronary Prevention Study (WOSCOPS), have contributed greatly to alleviating these concerns.

    In this article, a review of the epidemiologic evidence supporting the use of lipid modification will be presented, including important trials and meta-analyses, and the cost-effectiveness of lipid-modifying treatment will be discussed.

    Mots-clés Pascal : Hypolipémiant, Traitement, Chimiothérapie, Cardiopathie coronaire, Prévention, Efficacité traitement, Dyslipémie, Facteur risque, Homme, Revue bibliographique, Coût, Economie santé, Epidémiologie, Lipide, Appareil circulatoire pathologie, Métabolisme pathologie

    Mots-clés Pascal anglais : Antilipemic agent, Treatment, Chemotherapy, Coronary heart disease, Prevention, Treatment efficiency, Dyslipemia, Risk factor, Human, Bibliographic review, Costs, Health economy, Epidemiology, Lipids, Cardiovascular disease, Metabolic diseases

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0076208

    Code Inist : 002B02N. Création : 31/05/1999.